Agreements for a total of 38 biomedical projects were signed to promote the industry's development in Wuxi, Jiangsu province during the 2021 Taihu Bay Future Healthcare Conference, according to a new conference for the event on April 28.
The event was sponsored by the local government of Wuxi and attended by experts, industry insiders, and business partners, who discussed development trends and industrial policies relating to the life science and healthcare industries.
Many industry insiders are optimistic about digital medicine driving the development of Wuxi's biomedical industry.
Li Jian, head of Intel's medical and life sciences division in China, said that the combination of precision medicine and artificial intelligence can reshape the new pattern of medical care and bring dividends to the future life and health industry.
Leon Wang, executive vice-president of AstraZeneca, suggested Wuxi focus on two industrial heavyweights –AstraZeneca and WuXi Apptec – to carry out development in different districts.
Wuxi has attached heavy importance to the development of a modern biopharmaceutical industry, and the city has released a series of measures and working plans to support its rapid development in recent years.
By 2020, the city was home to 1,502 biopharmaceutical enterprises, with an industrial scale of 113.6 billion yuan ($17.5 billion).
The conference helped make clear the development trends of Wuxi's biomedical industry – the city will continue making use of its resources to achieve breakthroughs in core technologies, and work to develop medical devices, digital medical treatment, precision medical treatment, health food, and medical services, according to officials.
